Unknown

Dataset Information

Brivanib in combination with Notch3 silencing shows potent activity in tumour models.


ABSTRACT:

Background

Sorafenib is the first targeted agent proven to improve survival of patients with advanced hepatocellular carcinoma (HCC) and it has been used in first line treatments with heterogeneous response across patients. Most of the promising agents evaluated in first-line or second-line phase III trials for HCC failed to improve patient survival. The absence of molecular characterisation, including the identification of pathways driving resistance might be responsible for these disappointing results.

Methods

2D DIGE and MS analyses were used to reveal proteomic signatures resulting from Notch3 inhibition in HepG2 cells, combined with brivanib treatment. The therapeutic potential of Notch3 inhibition combined with brivanib treatment was also demonstrated in a rat model of

SUBMITTER: Giovannini C 

PROVIDER: S-EPMC6461893 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature